🔎 Trials Near Me

Home › Alcohol Use Disorder (AUD) › NCT07118618

Probenecid Administration for Alcohol Craving and Consumption

RecruitingPhase 2

Probenecid, Pannexin 1 Channels for Alcohol Use Disorder

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* • Male or female, ≥18 years.

  * women \>7 drinks/week; men \>14 drinks/week.
  * meet moderate to severe AUD score for DSM-5 criteria.
  * Breath Alcohol Content (BrAC)=0.00 at each visit.
  * in good health as confirmed by medical history, physical examination and lab tests.
  * willing to adhere to the study procedures.
  * understand informed consent and questionnaires in English at an 8th grade level.

Exclusion Criteria:

* • Women who are breastfeeding or positive urine test for pregnancy.

  * clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin \>150% of the upper normal limit, ALT/AST \>300% the UNL, creatinine clearance ≤60 dl/min
  * meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses
  * medications that reduce alcohol consumption (naltrexone, disulfiram).
  * use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration).
  * history of suicide attempts in the last three years.
  * current diagnosis of a moderate or severe cannabis use disorder as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.
  * current diagnosis of another substance disorder at any severity, other than nicotine, as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline.
  * current use of medications that may interact with probenecid.
  * history of hypersensitivity to sulfa drugs.

About the study

This study proposes a 16-week, between-subject, double-blind, randomized controlled trial (RCT) with probenecid (2g /day) compared to placebo in individuals with AUD to test if reduces craving and alcohol consumption.

What is being tested

Sponsor: Brown University · Participants: 120 · Started: Mar 14, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07118618

Locations in the U.S.

Rhode IslandBrown University, Providence

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.